# Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension

Study · id `cardio:ct-nct01303783` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01303783](<https://clinicaltrials.gov/study/NCT01303783>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01303783

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1381 participants.

## Technical summary

Registry record NCT01303783. Randomized; quadruple masking; primary purpose treatment. Start 2011-04 (registry gives no type); primary completion 2012-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 1381 participants (enrolled count; ClinicalTrials.gov record NCT01303783, source copy `cardio:ctgov-nct01303783-2017-04-18`, retrieved 2026-10-26)
- Start date: 2011-04 (registry gives no type) (ClinicalTrials.gov record NCT01303783, source copy `cardio:ctgov-nct01303783-2017-04-18`, retrieved 2026-10-26)
- Primary completion: 2012-05 (actual) (ClinicalTrials.gov record NCT01303783, source copy `cardio:ctgov-nct01303783-2017-04-18`, retrieved 2026-10-26)
- Completion: 2012-05 (actual) (ClinicalTrials.gov record NCT01303783, source copy `cardio:ctgov-nct01303783-2017-04-18`, retrieved 2026-10-26)
- Countries: United States; Argentina; Belgium; Brazil; Canada; Italy; Lithuania; Russia; South Africa; South Korea; Spain; Ukraine; United Kingdom (ClinicalTrials.gov record NCT01303783, source copy `cardio:ctgov-nct01303783-2017-04-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01303783-2017-04-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension
- Acronym: DISTINCT
- Condition: Hypertension, Essential
- Intervention (Drug): Candesartan cilexetil (Atacand), 4 mg
- Intervention (Drug): Candesartan cilexetil (Atacand), 8 mg
- Intervention (Drug): Nifedipine GITS (Adalat, BAYA1040), 20 mg
- Intervention (Drug): Nifedipine GITS (Adalat, BAYA1040), 30 mg
- Intervention (Drug): Nifedipine GITS (Adalat, BAYA1040), 60 mg
- Intervention (Drug): Placebo
- Intervention (Drug): Candesartan cilexetil (Atacand), 16 mg
- Intervention (Drug): Candesartan cilexetil (Atacand), 32 mg
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Nifedipine GITS/Candesartan Combination Therapy Lowers Blood Pressure Across Different Baseline Systolic and Diastolic Blood Pressure Categories: DISTINCT Study Subanalyses (`cardio:pubmed-26829251`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results (`cardio:pubmed-25144296`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 35c85d0502183ff0c043d80364b3f910b992b5ed72912e9df5d4696b1f73fdf0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
